drugset / Trial / NCT04599062

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

NCT04599062

Phase 1/2 Active not recruiting 8 enrolled John Rieth Amgen · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 46 people will take part in this study conducted by investigators at the University of Iowa.

Timeline

Start
2020-09-10
Primary completion
2023-02-07
Completion
2028-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified 8 ml Other

Indications